We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Ananya
Choudhury
ananya.choudhury@christie.nhs.uk
Parisa
Cutting
parisa.cutting@nhs.net
Dovile
Sutinyte
dovile.sutinyte@christie.nhs.uk
Malignant neoplasms of male genital organs
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
We will develop a way of predicting patient responses to Ra223 in a small blood sample using a molecular (RNA) signature measured in circulating prostate cancer cells (CTCs). This approach, called a ‘liquid biopsy’, can be used before, during and after treatment as it is easily repeated and is less invasive than taking a tumour sample. The main study aim is to make a simple blood test using the CTC RNA signature allowing doctors to know which prostate cancer patients are most likely to respond to Ra223 and spare patients’ toxicity if unlikely to respond. We will examine other molecules in the blood. These molecules, alongside CTCs, will be used to monitor patients during treatment. We think that during treatment, these molecules will decrease in responding patients and increase in resistant patients. We hope that molecule measurements may reveal which type of prostate cancer cells are sensitive and which are resistant to Ra223. We aim to develop a panel of blood tests to help doctors make better treatment decisions for their patients. We will also use patient CTCs to develop mouse prostate cancer models that can be used to understand treatment resistance and test new treatments.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
1. Patients must not have a history of other malignant diseases other than adequately treated non-melanotic skin cancer. 2. Any evidence of severe or uncontrolled systemic diseases which, in the view of the investigator, makes it undesirable for the patient to participate in the trial. 3. Evidence of significant clinical disorder or laboratory finding which, in the opinion of the investigator makes it undesirable for the patient to participate in the trial. Any other serious uncontrolled medical conditions 4. Any patient with a medical or psychiatric condition that impairs their ability to give informed consent
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Dr
Ananya
Choudhury
ananya.choudhury@christie.nhs.uk
Parisa
Cutting
parisa.cutting@nhs.net
Dovile
Sutinyte
dovile.sutinyte@christie.nhs.uk
The study is sponsored by University of Manchester and funded by PROSTATE CANCER UK .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 33614
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
